These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27376162)

  • 1. Sonidegib phosphate: new approval for basal cell carcinoma.
    Tibes R
    Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonidegib for the treatment of advanced basal cell carcinoma.
    Ramelyte E; Amann VC; Dummer R
    Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sonidegib: First Global Approval.
    Burness CB
    Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
    Chen L; Silapunt S; Migden MR
    Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
    Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs and combination strategies for basal cell carcinoma.
    Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 18. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
    Kunstfeld R
    Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
    Khoo AB; Ali FR; Lear JT
    Curr Opin Oncol; 2016 Mar; 28(2):180-4. PubMed ID: 26780190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.